Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company whose news flow centers on the development of novel therapies, with a particular focus on its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody in development for multiple solid tumors. Company press releases and related SEC filings provide regular updates on clinical progress, collaborations, and financial results.
News about Instil Bio frequently covers clinical trial milestones for AXN-2510/IMM2510, including Phase 1 monotherapy studies in relapsed or refractory solid tumors and data from Phase 1 and Phase 2 studies in non-small cell lung cancer (NSCLC) conducted by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in China. These updates have included preliminary safety and efficacy data, such as objective response rates and partial response rates in squamous and non-squamous NSCLC, as well as safety profiles in front-line NSCLC when ’2510 is combined with chemotherapy.
Investors and observers can also find corporate and financial updates in Instil Bio’s news, including quarterly financial results, operating expense details, and explanations of non-GAAP financial measures. Announcements have highlighted research and development spending, general and administrative expenses, and restructuring and impairment charges, along with reconciliations of GAAP to non-GAAP net loss and net loss per share.
Additional news items describe collaborations and corporate developments, such as the relationship with ImmuneOnco around ’2510, the role of Axion Bio, Inc. as a wholly-owned subsidiary dedicated to AXN-2510, leadership appointments including a Chief Medical Officer and board additions, and participation in healthcare conferences and investor events focused on the PD-(L)1xVEGF bispecific antibody landscape.
By following Instil Bio news, readers can track ongoing disclosures about AXN-2510’s clinical development, evolving collaboration arrangements, and the company’s financial and strategic updates as it advances its clinical-stage pipeline.
Instil Bio has resumed its Phase 1 trial of ITIL-306 for non-small cell lung cancer, ovarian cancer, and renal cell carcinoma after a voluntary pause. The company implemented additional quality safeguards in the manufacturing process. Initial data readout is expected in 2023 at a medical conference. Instil anticipates a cash runway extending into 2025, excluding potential financing from its Tarzana manufacturing site. The focus remains on developing next-generation tumor infiltrating lymphocyte therapies.
Instil Bio (NASDAQ: TIL) announced significant changes, including the discontinuation of its unmodified TIL programs like ITIL-168 and a workforce reduction of approximately 60% in the U.S. The company will focus on its CoStAR-TIL programs, particularly ITIL-306, now in a Phase 1 trial for various cancers. This strategic shift aims to enhance TIL therapies' efficacy and safety, with initial data expected next year. The decision to discontinue ITIL-168 was based on the prioritization of the CoStAR platform, emphasizing a realignment from a registration-focused to a development-stage model.
Instil Bio (TIL) announced a pause in the DELTA-1 trial of ITIL-168 due to manufacturing issues, with plans to provide updates in Q1 2023. Enrollment in DELTA-2 is deferred to focus on higher-priority projects. The company has dosed its first patient with ITIL-306 for non-small cell lung cancer, expecting initial results in 2023. Dr. Robert Hawkins is appointed Head of R&D, while former CMO Dr. Zachary Roberts has resigned. Instil confirms its cash runway into 2025, aided by a planned sale-leaseback of its Tarzana facility, despite reporting a net loss of $56.2 million in Q3 2022.
Instil Bio, Inc. (NASDAQ: TIL) announced poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting pre-clinical data for the ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor (CoStAR) platform. The data showed CoStAR enhances T-cell responses across various FRα expression levels, indicating potential for treating solid tumors. The ongoing Phase 1 study is focused on refractory solid tumors and excludes high-dose interleukin-2 in its treatment regimen.
Instil Bio, Inc. (Nasdaq: TIL) has voluntarily paused enrollment in its ITIL-168 and ITIL-306 clinical trials due to a decrease in the successful manufacturing rate of ITIL-168, impacting patient dosing. Despite this, no regulatory agencies have placed the trials on clinical hold. The company is conducting a comprehensive manufacturing analysis and plans to implement corrective actions. Instil confirmed its cash runway through 2025, contingent on a potential sale-leaseback of its Tarzana facility, and intends to provide a manufacturing update by early Q1 2023.
Instil Bio (Nasdaq: TIL) has commenced a Phase 1 study of ITIL-306, a groundbreaking TIL therapy targeting folate receptor alpha, designed to enhance tumor infiltrating lymphocyte (TIL) activity. The first patient, suffering from treatment-refractory non-small cell lung cancer, has been dosed. CoStAR-TIL therapy aims to improve TIL efficacy, potentially reducing reliance on high-dose interleukin-2. Initial clinical data is anticipated in 2023, marking a significant advancement in TIL therapy aimed at achieving durable remissions in challenging solid tumors.
Instil Bio, Inc. (Nasdaq: TIL), a clinical-stage biopharmaceutical company specializing in tumor infiltrating lymphocyte (TIL) therapies, will participate in the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 10:30 a.m. ET. This event includes a company presentation and Q&A session. Investors can access a live webcast of the presentation under the 'News & Events' section on the company's website. Instil is developing therapies for advanced melanoma and other solid tumors, leveraging its proprietary manufacturing processes for its lead product candidate, ITIL-168.
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio (Nasdaq: TIL) has announced its participation at the Morgan Stanley 20th Annual Global Healthcare Conference. The fireside chat will take place on September 12, 2022, at 2:50 p.m. ET. Investors can access a live webcast of the presentation on the company’s website, with an archived version available shortly after the event. Instil Bio focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, including its lead candidate ITIL-168 for advanced melanoma.
Instil Bio (NASDAQ: TIL) has appointed Tim Moore as Chief Operating Officer, bringing over 30 years of experience in biopharmaceutical manufacturing and operations to the company. Previously, Moore played a key role in launching Yescarta at Kite Pharma and led PACT Pharma as President and COO. CEO Bronson Crouch emphasized the addition of Moore to their executive team as a strategic move to enhance their capabilities in cell therapy development. Instil's ongoing focus is on advancing TIL therapies, especially ITIL-168 and ITIL-306, for treating solid tumors.
Instil Bio, Inc. reported its Q2 2022 results, highlighting continued enrollment in its DELTA-1 clinical trial of ITIL-168 for advanced melanoma, with top-line data expected in early 2024. The company aims to extend its cash runway into 2025, supported by a potential sale-leaseback of its Tarzana, CA manufacturing site. Key initiatives include the initiation of Phase 1 trials for ITIL-306 and ITIL-168 in combination with pembrolizumab for various cancers. However, Instil reported a net loss of $58.99 million, with total cash and equivalents down to $354.6 million from $454.1 million year-over-year.